IDO (mouse) (rec.) (His)

Indoleamine 2,3-dioxygenase 1; IDO; INDO

Specific Activity: >100?000U/mg protein with L-tryptophan as substrate and after addition of 7µM hemin for protein induction. One unit is defined as the amount of enzyme that produces 1nmol of kynurenine per hour.

1mg/ml

32160000

<1EU/µg purified protein (LAL test; Lonza).

liquid

Liquid. 0.2µm-filtered solution in 50mM TRIS-Cl, pH 7.4, containing 1mM EDTA.

After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.For maximum product recovery after thawing, centrifuge the vial before opening the cap.

Protein. Mouse IDO (aa 1-407) is fused at the C-terminus to a His-tag. Source: E. coli. Endotoxin content: <1EU/µg purified protein (LAL test; Lonza). Liquid. 0.2µm-filtered solution in 50mM TRIS-Cl, pH 7.4, containing 1mM EDTA. Purity: >90% (SDS-PAGE). IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

~40kDa (SDS-PAGE)

P28776

Plastic Vial

IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune system?s ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.

>90% (SDS-PAGE)

Mouse IDO1 (aa 1-407) is fused at the C-terminus to a His-tag.

E. coli

His

Non-hazardous

Other Proteins

12352202

Stable for at least 2 years after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.